Skip to main content
星昊医药 logo

星昊医药 — Investor Relations & Filings

Ticker · 920017 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2023-08-20 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920017

About 星昊医药

https://www.sunho.com.cn/

Beijing Sunho Pharmaceutical Co., Ltd. is a technology-driven enterprise specializing in the research, development, manufacturing, and commercialization of advanced pharmaceutical preparations. The company focuses on high-barrier drug delivery systems, including sustained-release, controlled-release, and complex injection technologies. Its core business encompasses the production of a diverse portfolio of chemical drugs and biological products, alongside comprehensive Contract Development and Manufacturing Organization (CDMO) services. Sunho Pharmaceutical operates modern, GMP-compliant production facilities designed to support the entire lifecycle of drug development, from pilot-scale testing to large-scale commercial manufacturing. By leveraging its proprietary formulation platforms, the company provides integrated solutions for complex dosage forms, catering to both domestic and international pharmaceutical markets.

Recent filings

Filing Released Lang Actions
独立董事关于第六届董事会第十三次会议相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion on various board meeting proposals, including fundraising usage, profit distribution, stock repurchase, and stock price stabilization. It references compliance with laws and regulations and the board meeting date but does not contain financial statements or detailed financial data. It is a regulatory announcement related to board meeting decisions and opinions rather than a full management report or financial report. The document length is short (2013 characters), and it serves as a formal opinion statement rather than a report itself. Therefore, it fits best under Regulatory Filings (RNS).
2023-08-20 Chinese
第六届董事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 13th meeting of the 6th Board of Directors of Beijing Xinghao Pharmaceutical Co., Ltd. It includes meeting details, attendance, and voting results on various proposals such as approval of the 2023 semi-annual report, fundraising usage, bank credit applications, share repurchase plans, and convening a shareholders meeting. The document references other filings where the full reports or announcements are published but itself is a formal board meeting resolution announcement. It does not contain the full financial report or detailed financial data but rather the board's decisions and approvals. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management. The document length (4911 characters) and content confirm it is not a full financial report or earnings release but a board meeting resolution announcement.
2023-08-20 Chinese
关于使用自有闲置资金购买理财产品的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Beijing Xinghao Pharmaceutical Co., Ltd. regarding the use of its own idle funds to purchase financial products. It details the purpose, amount, method, duration, risk analysis, and risk control measures related to the entrusted financial management. The document includes a board resolution date and emphasizes compliance with disclosure obligations. It does not contain financial statements, earnings data, or detailed financial reports. The document is relatively short (1132 characters) and serves as a disclosure of a financing-related activity rather than a full financial report or audit. Therefore, it fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities involving the use of idle funds for investment in financial products.
2023-08-20 Chinese
回购股份方案公告
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement regarding a share repurchase plan by Beijing Xinghao Pharmaceutical Co., Ltd. It includes specifics about the purpose, method, price limits, quantity, funding source, implementation period, and expected impact on shareholding structure. It also discusses management's analysis of the financial impact and authorizations from the board and shareholders. The content is focused on the company's plan to buy back its own shares to stabilize stock price and implement equity incentives. There are no financial statements or earnings data, nor is it a report or presentation. This fits the definition of a Transaction in Own Shares (POS) filing, which covers share repurchase announcements and plans.
2023-08-20 Chinese
关于实施稳定股价方案的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement by Beijing Xinghao Pharmaceutical Co., Ltd. regarding the implementation of a stock price stabilization plan involving share repurchases. It details the conditions triggering the plan, the repurchase method, price limits, expected share quantities, and constraints on the company and its controlling shareholders. The document is a formal announcement about a capital market action (share repurchase) to stabilize stock price, not a financial report or earnings release. It does not contain financial statements or earnings data but focuses on the share repurchase plan and related governance. Therefore, it fits best under the category of Transaction in Own Shares (POS), which covers company announcements about buying back its own shares.
2023-08-20 Chinese
2023年半年度权益分派预案公告
Notice of Dividend Amount Classification · 95% confidence The document is a detailed announcement regarding the company's 2023 semi-annual profit distribution plan, including dividend payout details, board and supervisory committee approvals, independent director opinions, and references to company bylaws on profit distribution. It discusses the proposed cash dividend per share, the basis for calculation, and the procedural steps for approval and implementation. The document does not contain actual financial statements or comprehensive financial performance data but focuses on the dividend distribution plan and related governance procedures. The document length is 4369 characters, which is relatively short but contains substantive content about dividend distribution rather than just announcing the publication of a report. Therefore, it fits best under the category of Notice of Dividend Amount (DIV), which covers announcements of dividend amounts, payment dates, and details for shareholders.
2023-08-20 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.